Patient-Focused Treatment Decisions in Advanced Renal Cell Carcinoma (RCC): Expert Strategies on New and Emerging Combinations

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive of the live session from the 2021 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from August 1, 2021 – August 1, 2022

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
Bristol Myers Squibb and Exelixis

Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport waste molecules from the blood to the urine. RCC is the most common type of kidney cancer in adults, responsible for approximately 90–95% of cases. In 2021, it is estimated that there will be approximately 76,080 new cases of kidney cancer, and about 13,780 people will die from the disease. Approximately 16% of patients with RCC will have metastases at diagnosis, and as many as 40% will demonstrate metastasis after primary surgical treatment for localized RCC. With a 5-year survival rate ranging from 5% to 12%, the prognosis for these patients is poor. Fortunately for patients with advanced RCC, many new treatments have recently become available or have completed clinical trials, especially in the area of immunotherapy combinations, giving clinicians new options to improve patient outcomes and quality of life. With so many new options becoming available for the healthcare community, clinicians and medical directors are struggling to stay abreast of all the changes in advanced RCC treatment, especially in the evolving area of immunotherapy and targeted therapy combinations. The prognosis for any treated renal cell cancer patient with progressing, recurring, or relapsing disease is poor, regardless of cell type or stage. Almost all patients with advanced renal cell cancer are incurable. The question and selection of further treatment depends on many factors, including if there has been any previous treatment and site of recurrence, as well as individual patient considerations. Fortunately, clinicians are being equipped with immune checkpoint inhibitors, both alone and in combination with targeted therapies, to integrate into the advanced RCC treatment paradigm, which individualize therapy for patients with advanced RCC, ultimately improving patient outcomes and quality of life. These new options, some of which have been approved in recent months, have shown improved efficacy and safety in advanced RCC.

Upon completion of this activity, participants will be able to:

  • Examine the clinical and economic burden of advanced renal cell carcinoma (RCC), including factors that contribute to poor prognosis and increased costs

  • Evaluate recent clinical data regarding mechanistic activity, efficacy, and safety of new and emerging immunotherapies and targeted therapies, including their combination, for advanced RCC

  • Explore the evolving role of immunotherapy and targeted therapy combinations in the first-line management of advanced RCC

  • Assess strategies to optimally sequence immunotherapy combinations in advanced RCC management

  • Review strategies to monitor and manage adverse events associated with immunotherapy and targeted therapy combinations in advanced RCC in order to improve patient adherence and quality of life

  • Discuss the managed care considerations of current and emerging immunotherapy and targeted therapy combinations by exploring where these agents fit into the current advanced RCC management paradigm


Faculty: Toni K. Choueiri, MD
Director, Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Co-Leader, Kidney Cancer Program
Dana-Farber/Harvard Cancer Center
Jerome and Nancy Kohlberg Professor of Medicine
Harvard Medical School


Dr. Choueiri serves on an advisory board and as a consultant for AstraZeneca, Aveo, Bayer, Eisai, Bristol Myers Squibb, EMD Serono, Exelixis, Lilly, Merck & Co., Novartis Pharmaceuticals Corporation, Roche, Sanofi, Takeda, Tempest, and Pfizer. He has received grant/research support from Bristol-Myers Squibb, Exelixis, and GlaxoSmithKline. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no financial relationships with ineligible companies to disclose.
Jeremy Williams has no financial relationships with ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial relationships with ineligible companies to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from
Bristol Myers Squibb and Exelixis

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue